Numerous studies have shown that antitumor vaccines based on synthetic peptides are safe and can induce both CD8 and CD4 tumor-specific T cell responses. However, clinical results are still scarce, and such approach to antitumor treatment has not gained a wide implication, yet. Recently, particular advances have been achieved due to tumor sequencing and the search for immunogenic neoantigens caused by mutations.
View Article and Find Full Text PDF